Shire has bagged the rights outside North America to Acceleron Pharma’s investigational duchenne muscular dystrophy drug inside a offer that could possibly be worth around $500 million.
The agreement covers Acceleron’s activin receptor kind IIB class of molecules, the lead prospect being ACE-031 for DMD, which can be inside a phase IIa trial. DMD is a fatal orphan muscle illness with no current treatment.
Cashwise, Shire will pay an upfront rate of $45 million and Acceleron is also eligible to receive further milestones of up to $165 million for the successful commercialisation of ACE-031 in DMD. The privately-held organization dependent in Cambridge, Massachusetts could receive an further $288 million related to other indications and molecules, along with royalties.
Sylvie Gregoire, president of Shire human being Genetic Therapies, mentioned the collaboration is “an exceptional strategic fit to the work that [the company] is already doing on behalf of individuals with unusual diseases”. She added that working with Acceleron “allows us to use our knowledge to help individuals struggling with this devastating disease, along with expand our pipeline into a manufacturer new therapeutic area”.